Covered recipient · General Payments record
VAMSI KOTA
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$18,136.16
15 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,215.00 | 2 |
| Consulting Fee | $6,570.00 | 3 |
| Food and Beverage | $334.71 | 7 |
| Education | $16.44 | 2 |
| Travel and Lodging | $0.01 | 1 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $8,251.12 | 2 |
| Novartis Pharmaceuticals Corporation | $6,943.34 | 6 |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,640.00 | 1 |
| Incyte Corporation | $201.19 | 3 |
| Kite Pharma, Inc. | $69.02 | 1 |
| Epizyme, Inc., | $16.17 | 1 |
| Agios Pharmaceuticals, Inc. | $15.32 | 1 |
Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
VAMSI KOTA
NPI 1790902393 · CMS profile ID 172817
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
AUGUSTA, GA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1790902393?year=2020&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- VAMSI KOTA, NPI 1790902393, CMS profile ID 172817. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790902393?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). VAMSI KOTA, NPI 1790902393, CMS profile ID 172817. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790902393?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- VAMSI KOTA, NPI 1790902393, CMS profile ID 172817, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1790902393?year=2020&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
15 matching records · $18,136.16 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–15 of 15.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,620.00 | 12/16/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 753370341 | CMS |
| PFIZER INC. | $8,250.00 | 12/11/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743636615 | CMS |
| Agios Pharmaceuticals, Inc. | $15.32 | 11/05/2020 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751971901 | CMS |
| Epizyme, Inc., | $16.17 | 09/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 748603113 | CMS |
| Incyte Corporation | $13.82 | 07/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 745804401 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,640.00 | 04/17/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747328705 | CMS |
| Novartis Pharmaceuticals Corporation | $1,310.00 | 04/03/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725981747 | CMS |
| PFIZER INC. | $1.12 | 03/06/2020 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743277125 | CMS |
| Novartis Pharmaceuticals Corporation | $28.73 | 02/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725981451 | CMS |
| Incyte Corporation | $65.78 | 02/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 745804367 | CMS |
| Kite Pharma, Inc. | $69.02 | 02/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 731507271 | CMS |
| Incyte Corporation | $121.59 | 02/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 745804385 | CMS |
| Novartis Pharmaceuticals Corporation | $19.60 | 02/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725981449 | CMS |
| Novartis Pharmaceuticals Corporation | $0.01 | 02/19/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725981743 | CMS |
| Novartis Pharmaceuticals Corporation | $2,965.00 | 02/19/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725981745 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $132,060.46 | 16 |
| PY2024 | Recipient | $4,666.04 | 2 |
| PY2024 | Principal investigator | $39,767.00 | 22 |
| PY2023 | Recipient | $11,715.50 | 3 |
| PY2023 | Principal investigator | $52,606.84 | 7 |
| PY2022 | Recipient | $9,994.00 | 10 |
| PY2022 | Principal investigator | $107,035.90 | 12 |
| PY2021 | Recipient | $8,130.00 | 4 |
| PY2021 | Principal investigator | $310,967.41 | 28 |
| PY2020 | Recipient | $17,342.00 | 13 |
| PY2020 | Principal investigator | $404,017.84 | 37 |
| PY2019 | Principal investigator | $397,422.88 | 40 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
40 records in PY2019
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $16,892.00 | 12/17/2019 | Non-covered Recipient Entity Georgia Cancer Center Augusta University AUMC | A SINGLE ARM OPENLABEL PHASE 4 STUDY EVALUATING QT INTERVAL PHARMACOKINETICS AND SAFETY OF GEMT | No dispute reported | 06/30/2026 | 671682579 |
| Principal investigator 1 | PFIZER INC. | $162.50 | 12/11/2019 | Covered Recipient Teaching Hospital EMORY UNIVERSITY HOSPITAL | AN OPENLABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA CML WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008 | No dispute reported | 06/30/2026 | 671678441 |
| Principal investigator 1 | Incyte Corporation | $30.40 | 12/09/2019 | Non-covered Recipient Entity GEORGIA CANCER CENTER | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 666519519 |
| Principal investigator 1 | Incyte Corporation | $254.16 | 12/09/2019 | Non-covered Recipient Entity GEORGIA CANCER CENTER | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 666519521 |
| Principal investigator 1 | Incyte Corporation | $40.10 | 12/09/2019 | Non-covered Recipient Entity GEORGIA CANCER CENTER | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 666519523 |
| Principal investigator 1 | Incyte Corporation | $23.40 | 12/09/2019 | Non-covered Recipient Entity GEORGIA CANCER CENTER | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 666519525 |
| Principal investigator 1 | Incyte Corporation | $57.30 | 12/09/2019 | Non-covered Recipient Entity GEORGIA CANCER CENTER | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 666519527 |
| Principal investigator 1 | Incyte Corporation | $40.10 | 12/09/2019 | Non-covered Recipient Entity GEORGIA CANCER CENTER | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 666519577 |
| Principal investigator 1 | PFIZER INC. | $325.00 | 11/13/2019 | Covered Recipient Teaching Hospital EMORY UNIVERSITY HOSPITAL | AN OPENLABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA CML WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008 | No dispute reported | 06/30/2026 | 671673053 |
| Principal investigator 1 | PFIZER INC. | $33,784.00 | 11/04/2019 | Non-covered Recipient Entity Georgia Cancer Center Augusta University AUMC | A SINGLE ARM OPENLABEL PHASE 4 STUDY EVALUATING QT INTERVAL PHARMACOKINETICS AND SAFETY OF GEMT | No dispute reported | 06/30/2026 | 671682593 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,566.55 | 10/07/2019 | Non-covered Recipient Entity AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC | An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL | No dispute reported | 06/30/2026 | 686168905 |
| Principal investigator 1 | Kadmon Corporation LLC | $96.00 | 10/01/2019 | Non-covered Recipient Entity Augusta University | A Phase 2 Randomized Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease cGVHD After at Least 2 Prior Lines of Systemic Therapy | No dispute reported | 06/30/2026 | 686021197 |
| Principal investigator 1 | Amgen Inc. | $58,830.00 | 09/11/2019 | Non-covered Recipient Entity AUGUSTA UNIVERSITY RESEARCH INSTITU | Multicenter Assessment of Outcomes in r/r Acute Myeloid Leukemia | No dispute reported | 06/30/2026 | 675783131 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $20,375.00 | 08/26/2019 | Non-covered Recipient Entity AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC | An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL | No dispute reported | 06/30/2026 | 686168907 |
| Principal investigator 1 | PFIZER INC. | $650.00 | 07/17/2019 | Covered Recipient Teaching Hospital EMORY UNIVERSITY HOSPITAL | AN OPENLABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA CML WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008 | No dispute reported | 06/30/2026 | 671673001 |
| Principal investigator 1 | PFIZER INC. | $33,784.00 | 07/16/2019 | Non-covered Recipient Entity Georgia Cancer Center Augusta University AUMC | A SINGLE ARM OPENLABEL PHASE 4 STUDY EVALUATING QT INTERVAL PHARMACOKINETICS AND SAFETY OF GEMT | No dispute reported | 06/30/2026 | 671682581 |
| Principal investigator 1 | PFIZER INC. | $74,633.05 | 07/09/2019 | Covered Recipient Teaching Hospital EMORY UNIVERSITY HOSPITAL | A MULTICENTER PHASE 3 RANDOMIZED OPENLABEL STUDY OF BOSUTINIB VERSUS IMATINIB IN ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA | No dispute reported | 06/30/2026 | 671688101 |
| Principal investigator 1 | PFIZER INC. | $2,961.00 | 06/24/2019 | Covered Recipient Teaching Hospital EMORY UNIVERSITY HOSPITAL | A MULTICENTER PHASE 3 RANDOMIZED OPENLABEL STUDY OF BOSUTINIB VERSUS IMATINIB IN ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA | No dispute reported | 06/30/2026 | 671668105 |
| Principal investigator 1 | PFIZER INC. | $70.00 | 05/29/2019 | Non-covered Recipient Entity Augusta University | A SINGLE ARM OPENLABEL PHASE 4 STUDY EVALUATING QT INTERVAL PHARMACOKINETICS AND SAFETY OF GEMT | No dispute reported | 06/30/2026 | 671672225 |
| Principal investigator 1 | Incyte Corporation | $2.92 | 05/08/2019 | Non-covered Recipient Entity GEORGIA CANCER CENTER | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 666519401 |
| Principal investigator 1 | Incyte Corporation | $31.91 | 05/08/2019 | Non-covered Recipient Entity GEORGIA CANCER CENTER | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 666519403 |
| Principal investigator 1 | Incyte Corporation | $23.40 | 05/08/2019 | Non-covered Recipient Entity GEORGIA CANCER CENTER | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 666519405 |
| Principal investigator 1 | Incyte Corporation | $10.88 | 05/08/2019 | Non-covered Recipient Entity GEORGIA CANCER CENTER | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 666519407 |
| Principal investigator 1 | Incyte Corporation | $6.08 | 05/08/2019 | Non-covered Recipient Entity GEORGIA CANCER CENTER | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 666519409 |
| Principal investigator 1 | Incyte Corporation | $80.20 | 05/08/2019 | Non-covered Recipient Entity GEORGIA CANCER CENTER | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 666519411 |
| Principal investigator 1 | Incyte Corporation | $36.29 | 05/08/2019 | Non-covered Recipient Entity GEORGIA CANCER CENTER | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 666519413 |
| Principal investigator 1 | Incyte Corporation | $254.16 | 05/08/2019 | Non-covered Recipient Entity GEORGIA CANCER CENTER | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 666519415 |
| Principal investigator 1 | Incyte Corporation | $20.91 | 05/08/2019 | Non-covered Recipient Entity GEORGIA CANCER CENTER | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 666519417 |
| Principal investigator 1 | Incyte Corporation | $57.30 | 05/08/2019 | Non-covered Recipient Entity GEORGIA CANCER CENTER | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 666519419 |
| Principal investigator 1 | Incyte Corporation | $30.40 | 05/08/2019 | Non-covered Recipient Entity GEORGIA CANCER CENTER | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 666519421 |
| Principal investigator 1 | PFIZER INC. | $149,266.10 | 04/12/2019 | Covered Recipient Teaching Hospital EMORY UNIVERSITY HOSPITAL | A MULTICENTER PHASE 3 RANDOMIZED OPENLABEL STUDY OF BOSUTINIB VERSUS IMATINIB IN ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA | No dispute reported | 06/30/2026 | 671677113 |
| Principal investigator 1 | PFIZER INC. | $750.00 | 03/18/2019 | Covered Recipient Teaching Hospital EMORY UNIVERSITY HOSPITAL | A MULTICENTER PHASE 3 RANDOMIZED OPENLABEL STUDY OF BOSUTINIB VERSUS IMATINIB IN ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA | No dispute reported | 06/30/2026 | 671671111 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $45.66 | 01/19/2019 | Non-covered Recipient Entity Meeting Incentives Worldwide Inc | An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL | No dispute reported | 06/30/2026 | 686168821 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $21.63 | 01/19/2019 | Non-covered Recipient Entity Meeting Incentives Worldwide Inc | An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL | No dispute reported | 06/30/2026 | 686168823 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $30.04 | 01/19/2019 | Non-covered Recipient Entity Meeting Incentives Worldwide Inc | An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL | No dispute reported | 06/30/2026 | 686168825 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $60.08 | 01/19/2019 | Non-covered Recipient Entity Meeting Incentives Worldwide Inc | An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL | No dispute reported | 06/30/2026 | 686168901 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $21.63 | 01/19/2019 | Non-covered Recipient Entity Meeting Incentives Worldwide Inc | An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL | No dispute reported | 06/30/2026 | 686168903 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $246.53 | 01/18/2019 | Non-covered Recipient Entity Meeting Incentives Worldwide Inc | An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL | No dispute reported | 06/30/2026 | 686168817 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $162.20 | 01/18/2019 | Non-covered Recipient Entity Meeting Incentives Worldwide Inc | An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL | No dispute reported | 06/30/2026 | 686168819 |
| Principal investigator 1 | PFIZER INC. | $1,690.00 | 01/03/2019 | Covered Recipient Teaching Hospital EMORY UNIVERSITY HOSPITAL | AN OPENLABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA CML WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008 | No dispute reported | 06/30/2026 | 671675707 |